AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2028

Conditions
Duchenne Muscular Dystrophy
Interventions
GENETIC

RGX-202

RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin

Trial Locations (16)

23298

RECRUITING

Children's Hospital of Richmond at Virginia Commonwealth University, Richmond

23510

RECRUITING

Children's Hospital of the King's Daughters, Norfolk

30329

RECRUITING

Rare Disease Research, Atlanta

45229

NOT_YET_RECRUITING

Cincinnati Children's, Cincinnati

52242

RECRUITING

University of Iowa, Iowa City

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

72202

RECRUITING

Arkansas Children's Hospital, Little Rock

75390

RECRUITING

The University of Texas Southwestern Medical Center, Dallas

80045

RECRUITING

Children's Hospital Colorado, Aurora

94304

RECRUITING

Stanford School of Medicine /Division of Neuromuscular Medicine, Palo Alto

97239

RECRUITING

Oregon Health & Science University, Portland

01608

RECRUITING

University of Massachusetts Chan Medical School, Worcester

T3B 6A

NOT_YET_RECRUITING

Alberta Children's Hospital, Calgary

V65 3N1

RECRUITING

BC Children's Hospital, Vancouver

Unknown

RECRUITING

Children's Hospital London Health Science Centre, London

K1H 8L1

RECRUITING

Children's Hospital of Eastern Ontario, Ottawa

All Listed Sponsors
lead

REGENXBIO Inc.

INDUSTRY